Acute Ischemic Stroke

Neurology·MeSH: Ischemic Stroke

Prevalence

1008.3 / 100K

Incidence

109.6 / 100K/yr

18 drugs in development·9 companies·12 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
tak-755	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-755	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Tenecteplase	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(11)

Drug	Company
Acetylcysteine	Cidara Therapeutics, Inc. (CDTX)
Acetylcysteine	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Acetylcysteine	PROTHENA CORP PUBLIC LTD CO (PRTA)
Acetylcysteine	Filana Therapeutics Inc. (FLNA)
Acetylcysteine	Structure Therapeutics Inc. (GPCR)
Dextrose in Water	Structure Therapeutics Inc. (GPCR)
Dextrose in Water	Filana Therapeutics Inc. (FLNA)
Dextrose in Water	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Dextrose in Water	PROTHENA CORP PUBLIC LTD CO (PRTA)
Dextrose in Water	Cidara Therapeutics, Inc. (CDTX)
TAK-755	Merus N.V. (MRUS)

Phase 1(1)

Drug	Company
mycophenolate acid	Cidara Therapeutics, Inc. (CDTX)

Phase 4(3)

Drug	Company
Acetylsalicylic acid	Cidara Therapeutics, Inc. (CDTX)
Tirofiban	Cidara Therapeutics, Inc. (CDTX)
Tirofiban	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 18 drugs in development for Acute Ischemic Stroke across 9 companies.

There are 12 clinical trials targeting Acute Ischemic Stroke tracked by BioSniper.

The estimated prevalence of Acute Ischemic Stroke is approximately 1008.3 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.